The stock price of Veru Inc. (NASDAQ: VERU), a biopharmaceuticals company focused on oncology medicines, has seen a monstrous 112% rise over the last ten trading days, while it’s up 47% over the last ...

--International Study Establishes the Role of Androgen Receptor as a Tumor Suppressor in ER+ Advanced Breast Cancer-- --Preclinical Studies Support Enobosarm’s Novel Mechanism of Action as an AR ...

Veru noted in its filing that there can be no assurance as to whether or when it will be able to receive any cash proceeds from the Series D Preferred Stock, the warrants, or any shares of Onconetix ...

Veru's candidate, sabizabulin, appears to be both safe and effective at treating severe COVID-19. The company could get the medicine to the market very quickly if regulators give the green light. The ...

Veru's valuation has both soared and crashed in 2022 due to its COVID-19 drug. The company recently reported underwhelming earnings numbers, which only gave investors more of a reason to be bearish on ...

Price change The price of VERU shares has increased $0.04 since the market last closed. This is a 1.91% rise. Closed at $2.13. The stock has remained unchanged in after-hours trading. Veru, Inc. is a ...

MIAMI, FL, March 09, 2026 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic ...

Drug developer Veru Inc on Tuesday said it plans to proceed with a late-stage trial of its COVID-19 pill, weeks after the U.S. health regulator declined to authorize the oral drug to treat high-risk ...

Additional information on the meeting can be found on the following website: https://obesityweek.org/. About Veru Inc. Veru is a late clinical stage biopharmaceutical ...

After a stellar 3x rise since the March 23 levels of last year, at the current price of around $10 per share we believe Veru Inc. stock (NASDAQ: VERU), a biopharmaceuticals company focused on oncology ...